Cargando…
Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
BACKGROUND: The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring source for immune checkpoint inhibitor. METHODS: Body...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805480/ https://www.ncbi.nlm.nih.gov/pubmed/31639056 http://dx.doi.org/10.1186/s40425-019-0708-8 |
_version_ | 1783461394816958464 |
---|---|
author | Park, Hyung Soon Kwon, Woo Sun Park, Sejung Jo, Eunji Lim, So Jung Lee, Choong-kun Lee, Jii Bum Jung, Minkyu Kim, Hyo Song Beom, Seung-Hoon Park, Jun Yong Kim, Tae Soo Chung, Hyun Cheol Rha, Sun Young |
author_facet | Park, Hyung Soon Kwon, Woo Sun Park, Sejung Jo, Eunji Lim, So Jung Lee, Choong-kun Lee, Jii Bum Jung, Minkyu Kim, Hyo Song Beom, Seung-Hoon Park, Jun Yong Kim, Tae Soo Chung, Hyun Cheol Rha, Sun Young |
author_sort | Park, Hyung Soon |
collection | PubMed |
description | BACKGROUND: The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring source for immune checkpoint inhibitor. METHODS: Body fluid including ascites and pleural fluid were obtained from 55 mGC patients and 24 matched blood. VEGF-A, IL-10, and TGF-β1 were measured and immune cells were profiled by fluorescence assisted cell sorting (FACS). RESULTS: VEGF-A and IL-10 were significantly higher in body fluid than in plasma of mGC. Proportion of T lymphocytes with CD69 or PD-1, memory T cell marked with CD45RO, and number of Foxp3+ T regulatory cells (Tregs) were significantly higher in body fluid than those in blood of mGC. Proportion of CD8 T lymphocyte with memory marker (CD45RO) and activation marker (HLA-DR), CD3 T lymphocyte with PD-1, and number of FoxP3+ Tregs were identified as independent prognostic factors. When patients were classified by molecular subgroups of primary tumor, VEGF-A was significantly higher in genomically stable (GS)-like group than that in chromosomal instability (CIN)-like group while PD-L1 positive tumor cells (%) showed opposite results. Monitoring immune dynamics using body fluid was also feasible. Early activated T cell marked with CD25 was significantly increased in chemotherapy treated group. CONCLUSIONS: By analyzing cytokines and proportion of immune cells in body fluid, prognosis of patients with mGC can be predicted. Immune monitoring using body fluid may provide more effective treatment for patients with mGC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0708-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6805480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68054802019-10-24 Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer Park, Hyung Soon Kwon, Woo Sun Park, Sejung Jo, Eunji Lim, So Jung Lee, Choong-kun Lee, Jii Bum Jung, Minkyu Kim, Hyo Song Beom, Seung-Hoon Park, Jun Yong Kim, Tae Soo Chung, Hyun Cheol Rha, Sun Young J Immunother Cancer Research Article BACKGROUND: The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring source for immune checkpoint inhibitor. METHODS: Body fluid including ascites and pleural fluid were obtained from 55 mGC patients and 24 matched blood. VEGF-A, IL-10, and TGF-β1 were measured and immune cells were profiled by fluorescence assisted cell sorting (FACS). RESULTS: VEGF-A and IL-10 were significantly higher in body fluid than in plasma of mGC. Proportion of T lymphocytes with CD69 or PD-1, memory T cell marked with CD45RO, and number of Foxp3+ T regulatory cells (Tregs) were significantly higher in body fluid than those in blood of mGC. Proportion of CD8 T lymphocyte with memory marker (CD45RO) and activation marker (HLA-DR), CD3 T lymphocyte with PD-1, and number of FoxP3+ Tregs were identified as independent prognostic factors. When patients were classified by molecular subgroups of primary tumor, VEGF-A was significantly higher in genomically stable (GS)-like group than that in chromosomal instability (CIN)-like group while PD-L1 positive tumor cells (%) showed opposite results. Monitoring immune dynamics using body fluid was also feasible. Early activated T cell marked with CD25 was significantly increased in chemotherapy treated group. CONCLUSIONS: By analyzing cytokines and proportion of immune cells in body fluid, prognosis of patients with mGC can be predicted. Immune monitoring using body fluid may provide more effective treatment for patients with mGC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0708-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-10-21 /pmc/articles/PMC6805480/ /pubmed/31639056 http://dx.doi.org/10.1186/s40425-019-0708-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Park, Hyung Soon Kwon, Woo Sun Park, Sejung Jo, Eunji Lim, So Jung Lee, Choong-kun Lee, Jii Bum Jung, Minkyu Kim, Hyo Song Beom, Seung-Hoon Park, Jun Yong Kim, Tae Soo Chung, Hyun Cheol Rha, Sun Young Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer |
title | Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer |
title_full | Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer |
title_fullStr | Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer |
title_full_unstemmed | Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer |
title_short | Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer |
title_sort | comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805480/ https://www.ncbi.nlm.nih.gov/pubmed/31639056 http://dx.doi.org/10.1186/s40425-019-0708-8 |
work_keys_str_mv | AT parkhyungsoon comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer AT kwonwoosun comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer AT parksejung comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer AT joeunji comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer AT limsojung comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer AT leechoongkun comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer AT leejiibum comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer AT jungminkyu comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer AT kimhyosong comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer AT beomseunghoon comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer AT parkjunyong comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer AT kimtaesoo comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer AT chunghyuncheol comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer AT rhasunyoung comprehensiveimmuneprofilingandimmunemonitoringusingbodyfluidofpatientswithmetastaticgastriccancer |